HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab
Author:
Funder
National Natural Science Foundation of China
Shanghai Municipal Education Commission—Gaofeng Clinical Medicine
Publisher
Elsevier BV
Subject
General Medicine,Surgery
Reference33 articles.
1. HER2 and breast cancer - a phenomenal success story;Hayes;N Engl J Med,2019
2. Amplification of a novel v-erbB-related gene in a human mammary carcinoma;King;Science,1985
3. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987
4. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information;Ryden;Breast Canc Res Treat,2008
5. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications;Montemurro;Ann Oncol,2013
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Pharmacoeconomic analysis of using empegfilgrastim for the treatment of early and locally advanced HER2+ breast cancer in the Russian Federation;FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology;2023-12-30
2. Clinical characteristics and treatment outcomes of invasive ductal and lobular carcinoma: analyses of 54,832 taiwan cancer registry index cases;Breast Cancer Research and Treatment;2023-07-20
3. Association of Enolase-1 with Prognosis and Immune Infiltration in Breast Cancer by Clinical Stage;Journal of Inflammation Research;2023-02
4. Impact of AJCC prognostic staging on prognosis and postmastectomy radiotherapy decision-making in hormone receptor-positive and HER2-positive breast cancer;BJS Open;2022-03-08
5. Bioinformatics Analysis Reveals the Related Role of miR-511-5p in the Progression of Breast Cancer;Journal of Healthcare Engineering;2022-02-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3